Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HINT1 | P49773 | 2/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.49 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | PNP | P00491 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18490626 | 0.91 | ADORA3 (0.52) | ADORA3HPGDHINT1NT5ESTING1 | |
| SCHEMBL7101375 | 0.89 | ADORA3 (0.53) | ADORA3HPGDHINT1NT5ESTING1 | |
| SCHEMBL29908542 | 0.88 | ADORA3 (0.52) | ADORA3HPGDHINT1NT5ESTING1 | |
| SCHEMBL12758342 | 0.88 | HINT1 (0.52) | ADORA3HPGDHINT1NT5ESTING1 | |
| SCHEMBL12151803 | 0.88 | HINT1 (0.52) | ADORA3HPGDHINT1NT5ESTING1 | |
| SCHEMBL1374868 | 0.88 | HINT1 (0.52) | ADORA3HPGDHINT1NT5ESTING1 | |
| SCHEMBL3427138 | 0.87 | ADORA3 (0.50) | ADORA3HPGDHINT1NT5ESTING1 | |
| SCHEMBL28911222 | 0.86 | HPGD (0.54) | ADORA3HPGDHINT1NT5ESTING1 | |
| SCHEMBL3437184 | 0.85 | NT5E (0.51) | ADORA3HPGDHINT1NT5ESTING1 | |
| SCHEMBL29771263 | 0.85 | HINT1 (0.51) | ADORA3HPGDHINT1NT5ESTING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205404-B1 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2007-04-17 | — | — | US | claimed |
| US-11492367-B2 | Cyclic dinucleotides as sting agonists | JANSSEN BIOTECH, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| EP-3573718-B1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2022-06-01 | — | — | EP | disclosed |
| WO-2018138685-A2 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH, INC. (US) | 2018-08-02 | — | — | WO | disclosed |
| US-7825238-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2010-11-02 | — | — | US | disclosed |
| US-7071173-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | MEDIVIR AB (SE) | 2006-06-08 | — | — | US | disclosed |
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | MEDIVIR AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-6974802-B2 | Treatment of viral infections using prodrugs of 2′,3-dideoxy,3′-fluoroguanosine | MEDIVIR AB (SE) | 2005-12-13 | — | — | US | disclosed |
| EP-1123935-B1 | 3'-Fluorinated guanosine derivatives for the treatment or prophylaxis of HBV or retroviral infections | MEDIVIR AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| US-6458772-B1 | Prodrugs | MEDIVIR AB (SE) | 2002-10-01 | — | — | US | disclosed |
| EP-1123935-A2 | 3'-Fluorinated guanosine derivatives for the treatment or prophylaxis of HBV or retroviral infections | MEDIVIR AB (SE) | 2001-08-16 | — | — | EP | disclosed |
| EP-0988304-B1 | NUCLEOSIDES ANALOGUES, SUCH AS ANTIVIRALS INCLUDING INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTASE AND THE DNA POLYMERASE OF HEPATITIS B VIRUS (HBV) | MEDIVIR AB (SE) | 2001-05-02 | — | — | EP | disclosed |
| EP-1058687-A1 | NUCLEOSIDES | MEDIVIR AB (SE) | 2000-12-13 | — | — | EP | disclosed |
| US-6110901-A | 3'-DEOXYRIBOCYTOSINE, 3'-DEOXYRIBOURACIL, AND/OR 3'-DEOXYRIBOGUANINE | AMERICAN CYANAMID COMPANY (US) | 2000-08-29 | — | — | US | disclosed |
| EP-0988304-A1 | NUCLEOSIDES ANALOGUES, SUCH AS ANTIVIRALS INCLUDING INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTASE AND THE DNA POLYMERASE OF HEPATITIS B VIRUS (HBV) | MEDIVIR AB (SE) | 2000-03-29 | — | — | EP | disclosed |
| WO-1999041268-A1 | NUCLEOSIDES | MEDIVIR AB (SE) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999009031-A1 | NUCLEOSIDES ANALOGUES, SUCH AS ANTIVIRALS INCLUDING INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTASE AND THE DNA POLYMERASE OF HEPATITIS B VIRUS (HBV) | MEDIVIR AB (SE) | 1999-02-25 | — | — | WO | disclosed |
| US-5223490-A | Treating breast cancer | UNIVERSITY OF LIVERPOOL (GB) | 1993-06-29 | — | — | US | disclosed |
| EP-0327200-A1 | Use of 3'-azido-3'-deoxythymidine for the manufacture of a medicament for the treatment of human breast carcinoma | THE UNIVERSITY OF LIVERPOOL (GB) | 1989-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11492367-B2 | Cyclic dinucleotides as sting agonists | STING1, CGAS, MAVS | ADORA3 384/4885HPGD 2125/4885HINT1 2052/4885 |
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | UNG, HAVCR2, EIF2AK2 | ADORA3 2150/4885HPGD 464/4885HINT1 2353/4885 |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | UNG, HAVCR2, EIF2AK2 | ADORA3 2150/4885HPGD 464/4885HINT1 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.